BioSpace News Archive

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has been selected to present at the American Association for Cancer Research (AACR) Annual Meeting

VANCOUVER, British Columbia, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms” or “PSF”), has completed its first shipment of cannabis under its supply agreement with Alberta Gaming, Liquor & Cannabis (AGLC). Pure Sunfarms’ recreational adult-use cannabis products will be available on Alberta’s only l

2019 revenues nearly doubled to more than $1.1 billion Exceeded improved 2019 guidance 2020 guidance reflects investment in strategic priorities Webcast today, February 26, 2020, at 11:30 a.m. Eastern Time

Feb. 26, 2020 12:00 UTC Triplet Therapeutics to Present at Cowen 40 th Annual Health Care Conference CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Triplet Therapeutics, Inc. , a biotechnology company harnessing new insights from human genetics to develop transformative treatments for repeat expansion disorders, today announced that Nessan Bermingham, Ph.D., Triplet’s co-founder, president and chief executive officer, will present at the Cowen and Company 40 th Annual Health Care Confere

Feb. 26, 2020 12:00 UTC CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences. Conference Presentation Details: Event: Cowen & Co. 40th Annual Health Care Conference Date/Time: Monday, Ma

MIT Technology Review’s “10 Breakthrough Technologies List of 2020” named Kebotix, a technology platform company for new chemicals and materials, as a key player in the field of AI-designed molecules.

Feb. 26, 2020 12:00 UTC Two of three dose cohorts in Phase 2 CMV vaccine (mRNA-1647) dose-confirmation study completed enrollment; third and final cohort rapidly enrolling Up to $2 billion to invest, including cash and investments, financing proceeds and potentially available grants; reiterates guidance that net cash used in operating activities and for purchases of property and equipment is expected to total between $490 million and $510 million in 2020 CAMBRIDGE, Ma

Two out of the first five patients dosed with IFX-1 achieved complete remission Dose escalation warranted by pharmacodynamic analysis and approved by relevant authorities for a total enrollment of 18 patients in 3 dose cohorts InflaRx to present initial data at the SVB Leerink Global Healthcare Conference today at 9:00 am EST (3:00 pm CET). JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory t

-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the U.S. Food and Drug A

- Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 - - Year-end 2019 cash reserves of $233 million - HAMILTON, Bermuda, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported fourth quarter and full-year 2019 financial resu